For context, another study found that tirzepatide led to an average weight loss of about 20 percent over 72 weeks, whereas Wegovy led to an average weight loss of roughly 14 percent
An estimated 20% of obese patients have minimal or no response to GLP-1s and around 40% stop treatment after 12 months mostly due to shortages, dosage inconvenience3 and costs
doi: 10.1016/j.foodres.2011.10.030 16 EncarnacionA
Some muscle loss is normal during weight loss, but the goal is to keep as much strength and function as possible
"It's kind of like, 'Oh, I want a little bit more,' and it's a little hard to push the plate aside." There's also plenty of other uncertainties about the short supply, fluctuating cost, and their long-term effects but he says even those hassles are worth it